Stöger H, Bauernhofer T, Kasparek A K, Schmid M, Moser R, Ploner F, Derstvenscheg E, Kuss I, Wilders-Truschnig M, Steindorfer P
Department of Internal Medicine, Karl Franzens University Graz, Austria.
Cancer Chemother Pharmacol. 1994;34(1):75-8. doi: 10.1007/BF00686116.
A total of 25 patients with advanced breast cancer were treated weekly with i.v. 5-fluorouracil at 350 mg/m2, folinic acid at 500 mg/m2, and epidoxorubicin at 35 mg/m2 as first-line chemotherapy for a maximum of 18 cycles. In all, 24 patients were evaluable for response. Overall, 1 patient achieved a complete response and 11 patients showed a partial response, for an objective response rate of 50%; the median duration of response was 18.3+ months and median survival amounted to 18.8+ months. Side effects were generally mild, with grade II leukopenia occurring in 10 patients and grade III leukopenia, in 1 patient. Other toxicity included nausea and vomiting (82%), diarrhea (48%), stomatitis (48%), and alopecia (92%), all of which were mainly restricted to WHO grades I and II. Our results suggest that leucovorin modulation of 5-fluorouracil can safely be incorporated into combination chemotherapy with epidoxorubicin on the investigated schedule. The observed response rate appears comparable with that obtained with other first-line regimens.
共有25例晚期乳腺癌患者接受每周一次的静脉化疗，使用剂量为350mg/m²的5-氟尿嘧啶、500mg/m²的亚叶酸钙和35mg/m²的表柔比星作为一线化疗方案，最多进行18个周期。总共24例患者可评估疗效。总体而言，1例患者达到完全缓解，11例患者出现部分缓解，客观缓解率为50%；缓解的中位持续时间为18.3+个月，中位生存期为18.8+个月。副作用一般较轻，10例患者出现II级白细胞减少，1例患者出现III级白细胞减少。其他毒性反应包括恶心和呕吐（82%）、腹泻（48%）、口腔炎（48%）和脱发（92%），所有这些主要局限于世界卫生组织I级和II级。我们的结果表明，在所研究的方案中，5-氟尿嘧啶的亚叶酸钙调节可以安全地纳入与表柔比星的联合化疗中。观察到的缓解率似乎与其他一线方案所获得的缓解率相当。
